Published in Am J Respir Crit Care Med on April 01, 1994
A centennial history of research on asthma pathogenesis. Am J Respir Cell Mol Biol (2005) 1.72
Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations. Thorax (2003) 1.47
Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol (2009) 1.40
Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax (2003) 1.22
Corticosteroid suppression of lipoxin A4 and leukotriene B4 from alveolar macrophages in severe asthma. Respir Res (2010) 0.99
Antileukotriene agents in asthma: the dart that kills the elephant? CMAJ (1999) 0.91
Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma. Multidiscip Respir Med (2012) 0.90
Contemporary treatment of children with critical and near-fatal asthma. Rev Bras Ter Intensiva (2016) 0.87
Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. Respir Res (2004) 0.86
Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation. J Inflamm Res (2010) 0.86
Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients. Thorax (1999) 0.85
Exhaled breath condensate cysteinyl leukotrienes and airway remodeling in childhood asthma: a pilot study. Respir Res (2006) 0.84
Montelukast in asthma: a review of its efficacy and place in therapy. Ther Adv Chronic Dis (2011) 0.83
Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. Br J Clin Pharmacol (2003) 0.81
The pulmonary physician in critical care . 12: Acute severe asthma in the intensive care unit. Thorax (2003) 0.80
Leukotriene receptor antagonist therapy. Postgrad Med J (2000) 0.79
Lower leukotriene C(4) levels in bronchoalveolar lavage fluid of asthmatic subjects after 2.5 years of inhaled corticosteroid therapy. Mediators Inflamm (1995) 0.79
Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study. Respir Res (2013) 0.78
Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit. J Pediatr Pharmacol Ther (2013) 0.78
Relation between bronchial responsiveness to inhaled leukotriene D4 and markers of leukotriene biosynthesis. Thorax (2005) 0.77
Blocking leukotrienes optimize asthma control: the BLOC survey. Ann Thorac Med (2007) 0.76
Effects of fluticasone propionate on arachidonic acid metabolites in BAL-fluid and methacholine dose-response curves in non-smoking atopic asthmatics. Mediators Inflamm (1996) 0.75
Retrospective cohort study of leukotriene receptor antagonist therapy for preventing upper respiratory infection-induced acute asthma exacerbations. Allergy Rhinol (Providence) (2013) 0.75
New treatments for asthma: the role of leukotriene modifier agents. J Natl Med Assoc (1999) 0.75
Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther (1970) 9.54
Bronchial hyperreactivity. Am Rev Respir Dis (1980) 4.77
Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med (1995) 3.91
Are Frozen Foods a Public Health Problem? Am J Public Health Nations Health (1947) 3.44
Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med (2005) 3.13
Urinary prostaglandins. Identification and origin. J Clin Invest (1975) 3.07
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol (1982) 2.69
The relative efficacy of guanethidine, methyldopa and pargyline as antihypertensive agents. N Engl J Med (1965) 2.64
Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med (1975) 2.63
Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med (1978) 2.50
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. Science (1976) 2.39
Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature (1994) 2.37
Clinical experience over 48 years with pheochromocytoma. Ann Surg (1999) 2.32
Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest (1970) 2.29
No evidence for lipid peroxidation in severe preeclampsia. Am J Obstet Gynecol (2001) 2.28
Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med (1999) 2.26
Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest (1981) 2.18
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest (1983) 2.13
Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med (1986) 2.03
Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest (1981) 2.03
Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J (1998) 1.89
Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man. Circulation (1979) 1.88
Ionophores stimulate prostaglandin and thromboxane biosynthesis. Proc Natl Acad Sci U S A (1977) 1.82
Effect of ganglionic blockade on bronchial reactivity in atopic subjects. Am Rev Respir Dis (1980) 1.81
Use of pulse oximetry to recognize severity of airflow obstruction in obstructive airway disease: correlation with pulsus paradoxus. Chest (1999) 1.77
Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol (1993) 1.76
Pharmacologic and endocrine aspects of carcinoid syndrome. Adv Pharmacol (1967) 1.74
Antagonism of the antihypertensive action of guanethidine sulfate by desipramine hydrochloride. JAMA (1967) 1.67
Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med (1980) 1.63
Suppression of plasma renin activity by indomethacin in man. Circ Res (1976) 1.62
Assessment of oxidant stress in allergic asthma by measurement of the major urinary metabolite of F2-isoprostane, 15-F2t-IsoP (8-iso-PGF2alpha). Clin Exp Allergy (2001) 1.62
Modulation of human neutrophil function by monohydroxy-eicosatetraenoic acids. Immunology (1980) 1.60
Brain metabolism in teenagers with attention-deficit hyperactivity disorder. Arch Gen Psychiatry (1993) 1.60
Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype. Br J Clin Pharmacol (1978) 1.57
Postpneumonic empyema in childhood: selecting appropriate therapy. J Pediatr Surg (1989) 1.56
Bartter's syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis. Am J Med (1976) 1.55
Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J (1991) 1.54
Measurement of 6-oxo-PGF1 alpha in human plasma using gas chromatography-mass spectrometry. Prostaglandins (1979) 1.48
Chlorpromazine reversal of the antihypertensive action of guanethidine. Lancet (1971) 1.43
Hypertension and fibromuscular dysplasia of the renal arteries. Surgery (1969) 1.42
Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. Free Radic Biol Med (2005) 1.42
Preferential role for NF-kappa B/Rel signaling in the type 1 but not type 2 T cell-dependent immune response in vivo. J Immunol (1999) 1.41
Inhibition of monoamine oxidase in man by furazolidone. Clin Pharmacol Ther (1968) 1.40
(R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nat Chem Biol (2011) 1.39
Prostaglandin thromboxane, and 12-hydroxy-5,8,10,14-eicosatetraenoic acid production by ionophore-stimulated rat serosal mast cells. Biochim Biophys Acta (1979) 1.39
Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther (1995) 1.38
Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci U S A (1990) 1.38
Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med (1978) 1.37
Biosynthesis of prostaglandin D2. 1. Formation of prostaglandin D2 by human platelets. Prostaglandins (1977) 1.36
Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J Biol Chem (1981) 1.35
Quantification of the major urinary metabolite of 15-F2t-isoprostane (8-iso-PGF2alpha) by a stable isotope dilution mass spectrometric assay. Anal Biochem (1999) 1.34
Respiratory syncytial virus infection prolongs methacholine-induced airway hyperresponsiveness in ovalbumin-sensitized mice. J Med Virol (1999) 1.34
Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther (1978) 1.33
Paracetemol poisoning--a brief report. Ir Med J (1977) 1.32
Blockade of the flush associated with metastatic gastric carcinoid by combined histamine H1 and H2 receptor antagonists. Evidence for an important role of H2 receptors in human vasculature. N Engl J Med (1979) 1.32
The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J Pharmacol Exp Ther (1997) 1.31
Arachidonic acid 15-lipoxygenase products from human eosinophils. J Biol Chem (1982) 1.30
Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol (1992) 1.28
Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. Am J Cardiol (1981) 1.28
Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation (1987) 1.27
Regional distribution of protease-resistant prion protein in fatal familial insomnia. Ann Neurol (1995) 1.26
Guanethidine and related agents. I. Mechanism of the selective blockade of adrenergic neurons and its antagonism by drugs. J Pharmacol Exp Ther (1970) 1.26
Oxygenation of arachidonic acid by hepatic monooxygenases. Isolation and metabolism of four epoxide intermediates. J Biol Chem (1982) 1.26
Effect of indomethacin and aspirin on gastric blood flow and acid secretion. J Pharmacol Exp Ther (1977) 1.25
Pharmacokinetics of indomethacin in the neonate. Relation of plasma indomethacin levels to response of the ductus arteriosus. N Engl J Med (1981) 1.24
Induced sputum eicosanoid concentrations in asthma. Am J Respir Crit Care Med (1999) 1.24
Cigarette smoking and hemostatic function. Am Heart J (1988) 1.23
Formation of a novel dihydroxy acid from arachidonic acid by lipoxygenase-catalyzed double oxygenation in rat mononuclear cells and human leukocytes. J Biol Chem (1982) 1.22
Renovascular hypertension: anatomic and renal function changes during drug therapy. Arch Surg (1981) 1.21
Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest (1983) 1.21
5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am J Physiol (1997) 1.20
Preparation and characterization of hydroperoxy-eicosatetraenoic acids (HPETEs). Prostaglandins (1980) 1.20
Operative management of renovascular hypertension. Results after a follow-up of fifteen to twenty-three years. J Vasc Surg (1984) 1.20
Effects of indomethacin on cyclic nucleotide levels and histamine release from rat serosal mast cells. J Immunol (1979) 1.20
Effect of ozone on bronchial reactivity in atopic and nonatopic subjects. Am Rev Respir Dis (1979) 1.19
The effects of arachidonic acid, prostaglandin E2 and prostaglandin F2alpha on the longitudinal stomach strip of the rat. J Pharmacol Exp Ther (1973) 1.18
Enrichment of rat tissue lipids with fatty acids that are prostaglandin precursors. Biochim Biophys Acta (1975) 1.16
Circadian rhythm of baroreflex reactivity and adrenergic vascular response. Cardiovasc Res (1980) 1.15
Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med (2000) 1.15
Sanitation and Quality Control in the Fishery Industries. Am J Public Health Nations Health (1937) 1.15
Stereospecific removal of the DR hydrogen atom at the 10-carbon of arachidonic acid in the biosynthesis of leukotriene A4 by human leukocytes. J Biol Chem (1982) 1.14
Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress. Am J Respir Crit Care Med (1999) 1.14
A second pathway of leukotriene biosynthesis in porcine leukocytes. Proc Natl Acad Sci U S A (1981) 1.13
Quantitative analysis of two dinor urinary metabolites of prostaglandin I2. Anal Biochem (1981) 1.13
Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials. N Engl J Med (1981) 1.12
Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am J Respir Crit Care Med (1998) 1.12
Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice. Am J Respir Crit Care Med (2000) 1.12
Immune interaction between respiratory syncytial virus infection and allergen sensitization critically depends on timing of challenges. J Infect Dis (2001) 1.12
Metabolism of prostaglandin D2 in the monkey. J Biol Chem (1979) 1.11
Increased excretion of leukotriene E4 during aspirin-induced asthma. J Lab Clin Med (1992) 1.11
Arachidonate 12-lipoxygenase purified from porcine leukocytes by immunoaffinity chromatography and its reactivity with hydroperoxyeicosatetraenoic acids. J Biol Chem (1986) 1.11
Prostaglandins and renin release: II. Assessment of renin secretion following infusion of PGI2,E2 and D2 into the renal artery of anesthetized dogs. Prostaglandins (1978) 1.11
Shock syndrome associated with mastocytosis: pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks. Adv Shock Res (1982) 1.10
Evidence for the release of bradykinin in carcinoid syndrome. J Clin Invest (1966) 1.10
Respiratory syncytial virus infection does not increase allergen-induced type 2 cytokine production, yet increases airway hyperresponsiveness in mice. J Med Virol (2001) 1.10
Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. Br Med J (Clin Res Ed) (1986) 1.10
Increased adventitial mast cells in a patient with coronary spasm. N Engl J Med (1985) 1.09